- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00004855
Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
A Randomized, Open-Label, Pilot Treatment Trial Evaluating Cellular Dynamics and Immune Restoration in Treatment-Naive HIV-Infected Subjects Receiving Either the Protease Inhibitor LPV/r or the Nucleoside Analogue Reverse Transcriptase Inhibitors d4T/3TC/Abacavir With the Non-Nucleoside Reverse Transcriptase Inhibitor Nevirapine
This study will compare an anti-HIV drug combination of protease inhibitor plus a nonnucleoside reverse transcriptase inhibitor (NNRTI) to one that includes three nucleoside reverse transcriptase inhibitors (NRTIs) plus an NNRTI. NNRTIs, NRTIs, and protease inhibitors are all types of anti-HIV drugs that block the virus in some way.
This study will try to find out if a treatment regimen containing a protease inhibitor plus an NNRTI has a different effect on the rise of CD4 cells compared to a treatment made up of three NRTIs plus an NNRTI. CD4 cells are cells of the immune system that fight infection. This study will also try to see if the combination of drugs used in this study is safe to use in HIV-positive patients.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study is designed to further define the dynamics and the mechanisms of the CD4 cell rise seen following administration of potent antiretroviral therapy. It will ascertain if treatment regimens containing nucleoside reverse transcriptase inhibitors (NRTIs) with a nonnucleoside reverse transcriptase inhibitor (NNRTI) have different effects on CD4 dynamics than regimens composed of a protease inhibitor with an NNRTI.
Patients are randomized to one of the two treatment arms listed below. They are stratified based on CD4 count and whether they choose to participate in substudy A5036s.
Arm A (protease inhibitor plus NNRTI regimen): At Day 0 (entry), patients begin taking LPV/RTV. At Day 3, patients add NVP, once daily for 2 weeks and then twice daily for the remainder of the study.
Arm B (triple reverse transcriptase inhibitors plus NNRTI regimen): At Day 0 (entry), patients begin taking 3TC plus d4T plus ABC. At Day 3, patients add NVP, once daily for 2 weeks and then twice daily for the remainder of the study.
HIV RNA analysis is performed at Weeks 4 and 5. If the mean is at least 1.0 log10 lower than the baseline HIV RNA, the patient may continue on study treatment. If the mean is not at least 1.0 log10 lower, however, patients are discontinued from the study by no later than Week 8. After 8 weeks of treatment, patients may change antiretroviral medications with permission of the protocol chair or vice chairs. Regular clinical evaluations are conducted. Blood is drawn to determine HIV RNA quantification, absolute CD4 and CD8 counts, immunological evaluations, telomere assays, and part is stored for future testing. Skin testing and return visits for delayed-type hypersensitivity to standard recall antigens are done on three occasions. Patients remain on the study for 48 weeks. Substudy A5036s evaluates viral dynamics during study treatment. Serial plasma samples are collected during the first 24 hours of treatment and at Day 3 and Week 4. Plasma HIV measurements are performed to differentiate between infectious and non-infectious particle production.
Studietyp
Inskrivning
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 900331079
- Univ of Southern California / LA County USC Med Ctr
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80262
- Univ of Colorado Health Sciences Ctr
-
Denver, Colorado, Förenta staterna, 80262
- Denver Dept of Health and Hosps
-
-
Hawaii
-
Honolulu, Hawaii, Förenta staterna, 96816
- Univ of Hawaii
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Northwestern Univ Med School
-
Chicago, Illinois, Förenta staterna, 60612
- Rush Presbyterian - Saint Luke's Med Ctr
-
Chicago, Illinois, Förenta staterna, 60612
- Cook County Hosp
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 462025250
- Indiana Univ Hosp
-
Indianapolis, Indiana, Förenta staterna, 46202
- Methodist Hosp of Indiana / Life Care Clinic
-
Indianapolis, Indiana, Förenta staterna, 46202
- Division of Inf Diseases/ Indiana Univ Hosp
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Johns Hopkins Hosp
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Beth Israel Deaconess - West Campus
-
-
New York
-
New York, New York, Förenta staterna, 10003
- Beth Israel Med Ctr
-
New York, New York, Förenta staterna, 10016
- Bellevue Hosp / New York Univ Med Ctr
-
New York, New York, Förenta staterna, 10029
- Mount Sinai Med Ctr
-
Rochester, New York, Förenta staterna, 14642
- Univ of Rochester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 275997215
- Univ of North Carolina
-
Durham, North Carolina, Förenta staterna, 27710
- Duke Univ Med Ctr
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 452670405
- Univ of Cincinnati
-
Cleveland, Ohio, Förenta staterna, 44106
- Case Western Reserve Univ
-
Cleveland, Ohio, Förenta staterna, 441091998
- MetroHealth Med Ctr
-
-
Rhode Island
-
Providence, Rhode Island, Förenta staterna, 02906
- Miriam Hosp / Brown Univ
-
-
Texas
-
Galveston, Texas, Förenta staterna, 775550435
- Univ of Texas Galveston
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria
Patients may be eligible for this study if they:
- Are 18 years of age or older.
- Are HIV-positive.
- Have a CD4 count of 500 cells/mm3 or less.
- Have a viral load greater than 5,000 and less than 100,000 copies/ml.
- Are willing to use barrier methods of birth control (such as condoms) during the study and for 12 weeks after stopping treatment.
- Will most likely respond well to nevirapine. This is determined by the results of a test.
Exclusion Criteria
Patients will not be eligible for this study if they:
- Have ever taken any anti-HIV drugs. (Seven days or less of treatment will be allowed if it was received more than 30 days before study entry.)
- Have pancreatitis (an inflamed pancreas) or hepatitis within 2 weeks of study entry.
- Are pregnant or breast-feeding.
- Actively abuse drugs or alcohol which their doctor feels would interfere with the ability to fulfill study requirements.
- Have taken any medications within 14 days of study entry that would interfere with the study drugs.
- Are receiving or need to receive chemotherapy.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
Samarbetspartners och utredare
Utredare
- Studiestol: Alan Landay
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunologiska bristsyndrom
- Immunsystemets sjukdomar
- HIV-infektioner
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Omvända transkriptashämmare
- Nukleinsyrasynteshämmare
- Enzyminhibitorer
- Anti-HIV-medel
- Antiretrovirala medel
- Antimetaboliter
- Proteashämmare
- Cytokrom P-450 CYP3A-hämmare
- Cytokrom P-450 enzymhämmare
- Cytokrom P-450 enzyminducerare
- Cytokrom P-450 CYP3A-inducerare
- HIV-proteashämmare
- Virala proteashämmare
- Nevirapin
- Ritonavir
- Lopinavir
- Lamivudin
- Stavudine
- Abacavir
Andra studie-ID-nummer
- A5014
- 10866 (Registeridentifierare: DAIDS ES)
- ACTG A5014
- AACTG A5014
- Substudy ACTG AA5036s
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-infektioner
-
Institut PasteurRekrytering
-
Duke UniversityAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
Catholic University of the Sacred HeartAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
The University of Texas Health Science Center,...EurofinsAvslutadOdontogen Deep Space Neck InfectionFörenta staterna
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekryteringCentral Line-associated Bloodstream Infection (CLABSI)Nederländerna
-
University of MalayaTeleflexRekryteringCLABSI - Central Line Associated Bloodstream InfectionMalaysia
-
Johns Hopkins UniversityAvslutadCLABSI - Central Line Associated Bloodstream InfectionFörenta staterna
-
National Taiwan University HospitalAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
National Taiwan University Hospital Hsin-Chu BranchAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
Port Said UniversityRekryteringCentral Line-associated Bloodstream Infection (CLABSI)Egypten
Kliniska prövningar på Nevirapin
-
Boehringer IngelheimAvslutadHIV-infektionerFörenta staterna, Botswana, Tyskland, Sydafrika
-
Boehringer IngelheimAvslutadHIV-infektionerFörenta staterna, Argentina, Australien, Belgien, Botswana, Kanada, Frankrike, Tyskland, Irland, Italien, Mexiko, Nederländerna, Polen, Portugal, Puerto Rico, Rumänien, Ryska Federationen, Sydafrika, Spanien, Schweiz, Storbritannien
-
Boehringer IngelheimAvslutadHIV-infektionerFörenta staterna, Frankrike, Tyskland, Storbritannien
-
Boehringer IngelheimAvslutad
-
Peking Union Medical CollegeMinistry of Science and Technology of the People´s Republic of ChinaAvslutad
-
Boehringer IngelheimAvslutad
-
Boehringer IngelheimAvslutadLeverinsufficiens | HIV-infektionerFrankrike, Förenta staterna, Spanien
-
Institut de Recherche pour le DeveloppementEunice Kennedy Shriver National Institute of Child Health and Human Development... och andra samarbetspartnersAvslutadHIV-infektioner | GraviditetThailand
-
Johns Hopkins Bloomberg School of Public HealthEunice Kennedy Shriver National Institute of Child Health and Human Development... och andra samarbetspartnersAvslutad
-
Tibotec BVBAAvslutad